08.15.14
NeuroVigil Inc. is making moved in brain research as it strikes a multi-year deal to help an unnamed pharmaceutical company as well as an alliance with the University of Basel in Switzerland to tackle Rett Syndrome, a lethal neurodevelopmental disorder that affects girls almost exclusively.
NeuroVigil’s proprietary suite of software algorithms and portable brain activity monitors was launched commercially in 2009 and is now a prevailing model for early central nervous system pharmaceutical research. The commercial agreement, five years in the making, is a win-win partnership for both NeuroVigil and the pharmaceutical company as it will greatly expand the latter’s research and development capabilities by gaining access to high-resolution and high-throughput data while augmenting NeuroVigil's exclusive biomarker databases. NeuroVigil will retain all rights to its data and any biomarkers discovered by either party and will not advise the pharmaceutical company on the pharmacological applications of its compounds. The uncapped agreement is unrestricted and both parties remain free to collaborate with other parties.
“This new collaboration heralds an advancement for both companies—to discover and promote innovative methods to monitor disease and ultimately improve human health,” said Philip Low, Ph.D., founder, chairman, CEO and chief scientific officer of NeuroVigil. “Our first research partnership grew out of Basel five years ago. We are delighted and honored to return to Basel and work with our new collaborators, and we are excited to focus our human based non-invasive neurotechnologies to develop a deeper understanding of some of Humanity’s most challenging and mysterious conditions.”
NeuroVigil develops non-invasive wireless brain recording technology with advanced computational analysis techniques applied exclusively on human data. The company has active programs in neuroengineering at its La Jolla, Calif. headquarters, and in computational neuroscience at its NASA satellite laboratory in Silicon Valley.
NeuroVigil’s proprietary suite of software algorithms and portable brain activity monitors was launched commercially in 2009 and is now a prevailing model for early central nervous system pharmaceutical research. The commercial agreement, five years in the making, is a win-win partnership for both NeuroVigil and the pharmaceutical company as it will greatly expand the latter’s research and development capabilities by gaining access to high-resolution and high-throughput data while augmenting NeuroVigil's exclusive biomarker databases. NeuroVigil will retain all rights to its data and any biomarkers discovered by either party and will not advise the pharmaceutical company on the pharmacological applications of its compounds. The uncapped agreement is unrestricted and both parties remain free to collaborate with other parties.
“This new collaboration heralds an advancement for both companies—to discover and promote innovative methods to monitor disease and ultimately improve human health,” said Philip Low, Ph.D., founder, chairman, CEO and chief scientific officer of NeuroVigil. “Our first research partnership grew out of Basel five years ago. We are delighted and honored to return to Basel and work with our new collaborators, and we are excited to focus our human based non-invasive neurotechnologies to develop a deeper understanding of some of Humanity’s most challenging and mysterious conditions.”
NeuroVigil develops non-invasive wireless brain recording technology with advanced computational analysis techniques applied exclusively on human data. The company has active programs in neuroengineering at its La Jolla, Calif. headquarters, and in computational neuroscience at its NASA satellite laboratory in Silicon Valley.